Goldman Sachs’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-864,081
| Closed | -$20.8M | – | 6274 |
|
|
2023
Q1 | $20.8M | Buy |
864,081
+644,811
| +294% | +$8.09M | ﹤0.01% | 1785 |
|
|
2022
Q4 | $2.32M | Sell |
219,270
-6,053
| -3% | -$48.8K | ﹤0.01% | 3833 |
|
|
2022
Q3 | $1.01M | Sell |
225,323
-116,388
| -34% | -$530K | ﹤0.01% | 4496 |
|
|
2022
Q2 | $1.37M | Buy |
341,711
+98,020
| +40% | +$465K | ﹤0.01% | 4380 |
|
|
2022
Q1 | $1.78M | Sell |
243,691
-25,889
| -10% | -$155K | ﹤0.01% | 4352 |
|
|
2021
Q4 | $1.51M | Buy |
269,580
+60,343
| +29% | +$383K | ﹤0.01% | 4486 |
|
|
2021
Q3 | $1.34M | Sell |
209,237
-123,363
| -37% | -$793K | ﹤0.01% | 4525 |
|
|
2021
Q2 | $2.8M | Sell |
332,600
-7,906
| -2% | -$63.8K | ﹤0.01% | 3895 |
|
|
2021
Q1 | $3.57M | Buy |
340,506
+267,517
| +367% | +$3.76M | ﹤0.01% | 3449 |
|
|
2020
Q4 | $1.24M | Sell |
72,989
-60,928
| -45% | -$913K | ﹤0.01% | 4060 |
|
|
2020
Q3 | $1.72M | Buy |
133,917
+27,302
| +26% | +$345K | ﹤0.01% | 3675 |
|
|
2020
Q2 | $1.5M | Buy |
106,615
+2,375
| +2% | +$30K | ﹤0.01% | 3655 |
|
|
2020
Q1 | $959K | Buy |
+104,240
| New | +$1.34M | ﹤0.01% | 3794 |
|
|
2019
Q2 | – | Sell |
-15,727
| Closed | -$36K | – | 5418 |
|
|
2019
Q1 | $36K | Sell |
15,727
-4,008
| -20% | -$9.41K | ﹤0.01% | 5023 |
|
|
2018
Q4 | $35K | Sell |
19,735
-2,165
| -10% | -$6.22K | ﹤0.01% | 5118 |
|
|
2018
Q3 | $88K | Buy |
+21,900
| New | +$86.6K | ﹤0.01% | 5180 |
|
Other funds holding PRVB
Goldman Sachs's PRVB Position: Q2 2023 in Review
Goldman Sachs sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 864,081 shares — an estimated $20.8M sold.
Goldman Sachs first reported a position in PRVB in Q3 2018 and held it in 16 quarters. The position peaked at $20.8M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Goldman Sachs reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Goldman Sachs sold 864,081 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $20.8M.
- Goldman Sachs first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 16 quarters.
- Goldman Sachs's Provention Bio, Inc. Common Stock position peaked at $20.8M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.